<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630525</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2011/22</org_study_id>
    <nct_id>NCT01630525</nct_id>
  </id_info>
  <brief_title>&quot; The Eyes Have it &quot; : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease</brief_title>
  <acronym>LYLO</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) has a prolonged prodromal phase before the stage of dementia. Subtle
      executive cognitive function deficits can be detected at this early pre-dementia phase, more
      than 10 years before dementia. Among them, the digit symbol substitution task (DSST) has been
      shown to be altered very early, up to 13 years before dementia. This test, as many others
      executive function tests, requires a fine control of visuomotor coordination. Like executive
      functions, eye movements, particularly voluntary-guided saccades, are under the control of
      the frontal lobe and fronto-parietal networks. Previous studies have shown a deterioration of
      voluntary saccades in AD using various paradigms. There are no data in prodromal AD, although
      the pathological process of the disease affects very early brain structures implicated in
      saccades execution (eg. caudate nucleus and pre-cuneus).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Saccades execution parameters</measure>
    <time_frame>Study visit (Up to 1 month after inclusion)</time_frame>
    <description>To demonstrate the alteration of saccade execution parameters (latency, velocity, precision, errors) during pro and anti-saccades, spatial decision and prediction tasks in prodromal AD compared to mild to moderate AD and aged-matched controls.
Variables recorded :
Saccades execution parameters :
Mean latency (msec),
Mean velocity (°/msec) and maximal velocity,
Accuracy or mean gain,
Mean percent of errors and corrected errors,
Mean percent of prediction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychology tests scores</measure>
    <time_frame>At inclusion (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-defined variables on visual exploration tasks (fixation number and durations, errors).</measure>
    <time_frame>Study visit (Up to 1 month after inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of point fixation in degraded areas and of visual attention induced cards</measure>
    <time_frame>Study visit (Up to 1 month after inclusion)</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Prodromal AD participants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Typical AD participants</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control participants</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuropsychological assessment</intervention_name>
    <description>Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).</description>
    <arm_group_label>Prodromal AD participants</arm_group_label>
    <arm_group_label>Typical AD participants</arm_group_label>
    <arm_group_label>Control participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ophthalmologic checkup</intervention_name>
    <description>Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).</description>
    <arm_group_label>Prodromal AD participants</arm_group_label>
    <arm_group_label>Typical AD participants</arm_group_label>
    <arm_group_label>Control participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Automated non-invasive oculometry</intervention_name>
    <description>Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).</description>
    <arm_group_label>Prodromal AD participants</arm_group_label>
    <arm_group_label>Typical AD participants</arm_group_label>
    <arm_group_label>Control participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Group A : 30 Prodromal Alzheimer Disease, Group B : 30 typical Alzheimer Disease, Group C :
        30 controls age-matched ± 5 years to Group A (to Group A) Total of 90 subjects.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patient groups:

          -  Age &gt;60 years

          -  Normal vision work-up : (corrected binocular visual acuity &gt; 8/10)

          -  Written informed consent

          -  Subjects affiliated to Social Security

        Group A: Prodromal AD.

          -  Memory complaints.

          -  Normal or slight restriction of IADL.

          -  &quot;hippocampal-type&quot; amnesic syndrome defined by poor free recall despite adequate (and
             controlled) encoding, decreased total recall because of insufficient effect of cuing
             or impaired recognition, numerous intrusions (RL/RI-16items)

          -  CDR (Clinical Dementia Rating Scale) ≥ 0,5

          -  Persistence of memory changes at a subsequent assessment (&gt;3 months)

          -  Absence of global cognitive deterioration (MMSE ≥24)

          -  Exclusion of other disorders that may cause mild cognitive impairment with adequate
             tests

          -  1.5 Tesla diagnosis MRI with at least T2, Flair transversal sections and coronal T1
             sections in the coronal plan. Absent or slight medio temporal/hippocampal atrophy or
             if available (non mandatory) characteristic CSF betaA42/tau ratio

        Group B: Typical AD (mild to moderate)

          -  NINDS-ADRDA diagnosis criteria

          -  MMSE ≥ 20

        Group C: Control subjects

          -  No memory or other significant cognitive complain.

          -  MMSE ≥ 24

        Exclusion Criteria:

        All groups :

          -  Clinically significant vision abnormality(P8 without glasses)

          -  Oculomotor deficit or strabismus

          -  Depression (GDS) with treatment

          -  Subjects unable to give their informed consent

        Controls :

          -  Memory or any other significant cognitive complain.

          -  Abnormalities at inclusion (V0) neuropsychology testing suggestive of a cognitive
             deficit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François TISON, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lyon UniversityHospital</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>neurodegenerative signs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

